Nobuhiko Ishizuka Selected Research

Nicorandil (SG 75)

3/2015	Nicorandil prevents sirolimus-induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation.
1/2013	Nicorandil ameliorated hypertensive renal injury without lowering blood pressure in spontaneously hypertensive rats.
11/2011	Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats.
9/2009	Nicorandil improves glomerular injury in rats with mesangioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors.
3/2009	Nicorandil attenuates FeCl(3)-induced thrombus formation through the inhibition of reactive oxygen species production.
11/2008	Nicorandil, a potassium channel opener and nitric oxide donor, improves the frequent urination without changing the blood pressure in rats with partial bladder outlet obstruction.
2/2008	Inhibitory effects of nicorandil, a K ATP channel opener and a nitric oxide donor, on overactive bladder in animal models.
1/2008	Nicorandil enhances the effect of endothelial nitric oxide under hypoxia-reoxygenation: role of the KATP channel.
11/2002	Nicorandil and leukocyte activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nobuhiko Ishizuka Research Topics

Disease

2	Thrombosis (Thrombus) 03/2015 - 03/2009
2	Proteinuria 01/2013 - 09/2009
2	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 11/2008 - 02/2008
1	Congenital Abnormalities (Deformity) 09/2016
1	Rheumatic Diseases (Rheumatism) 09/2016
1	Spontaneous Abortion (Miscarriage) 09/2016
1	Fibrosis (Cirrhosis) 01/2013
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2011
1	Hypertension (High Blood Pressure) 04/2011
1	Inflammation (Inflammations) 04/2011
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 04/2011
1	Glomerulonephritis 09/2009
1	Heart Failure 09/2009
1	Hypertrophy 09/2009
1	Nephritis 09/2009
1	Chronic Renal Insufficiency 09/2009
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 03/2009
1	Heart Diseases (Heart Disease) 02/2008
1	Overactive Urinary Bladder (Overactive Bladder) 02/2008
1	Urethral Obstruction 02/2008
1	Hypoxia (Hypoxemia) 01/2008
1	Myocardial Infarction 11/2002
1	Ischemia 11/2002

Drug/Important Bio-Agent (IBA)

9	Nicorandil (SG 75)IBA 03/2015 - 11/2002
3	KATP ChannelsIBA 03/2009 - 11/2002
3	Nitric Oxide DonorsIBA 11/2008 - 11/2002
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2008 - 11/2002
3	Adenosine Triphosphate (ATP)IBA 02/2008 - 11/2002
2	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2015 - 03/2009
2	PotassiumIBA 02/2008 - 11/2002
1	tocilizumab (atlizumab)FDA Link 09/2016
1	Sirolimus (Rapamycin)FDA Link 03/2015
1	Endothelins (Endothelin)IBA 01/2013
1	Proteins (Proteins, Gene)FDA Link 01/2013
1	Messenger RNA (mRNA)IBA 01/2013
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2013
1	Phosphates (Orthophosphate)IBA 04/2011
1	CreatinineIBA 04/2011
1	Parathyroid Hormone (Parathormone)IBA 04/2011
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 04/2011
1	Phosphorus (Red Phosphorus)IBA 04/2011
1	SodiumIBA 04/2011
1	Interleukin-6 (Interleukin 6)IBA 04/2011
1	Pharmaceutical PreparationsIBA 09/2009
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2009
1	Cardiotonic Agents (Cardiac Stimulants)IBA 09/2009
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 03/2009
1	Tirofiban (Aggrastat)FDA Link 03/2009
1	ferric chlorideIBA 03/2009
1	Potassium Channels (Potassium Channel)IBA 11/2008
1	Acetic Acid (Vinegar)FDA LinkGeneric 02/2008
1	Nitric Oxide Synthase (NO Synthase)IBA 02/2008
1	Superoxides (Superoxide)IBA 01/2008